Loomis Sayles & Co. L P Has $87.78 Million Stock Position in Glaukos Co. (NYSE:GKOS)

Loomis Sayles & Co. L P increased its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 21.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 673,751 shares of the medical instruments supplier's stock after buying an additional 119,527 shares during the quarter. Loomis Sayles & Co. L P owned about 1.22% of Glaukos worth $87,776,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. acquired a new position in shares of Glaukos during the second quarter valued at approximately $6,832,000. WCM Investment Management LLC raised its holdings in shares of Glaukos by 45.7% in the 3rd quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier's stock worth $12,721,000 after purchasing an additional 31,084 shares in the last quarter. First Turn Management LLC acquired a new stake in shares of Glaukos during the 3rd quarter valued at $12,520,000. Victory Capital Management Inc. lifted its holdings in shares of Glaukos by 421.8% during the third quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier's stock valued at $10,320,000 after purchasing an additional 64,031 shares during the last quarter. Finally, Seven Eight Capital LP acquired a new position in shares of Glaukos in the second quarter worth about $1,940,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Glaukos

In other news, Director Gilbert H. Kliman sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the sale, the director now owns 32,336 shares of the company's stock, valued at approximately $4,225,345.12. This trade represents a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

Glaukos Stock Performance

Glaukos stock traded down $1.06 on Monday, reaching $142.94. 661,845 shares of the stock were exchanged, compared to its average volume of 572,746. The firm has a fifty day moving average price of $132.40 and a two-hundred day moving average price of $123.80. Glaukos Co. has a twelve month low of $59.22 and a twelve month high of $146.86. The stock has a market cap of $7.88 billion, a PE ratio of -47.33 and a beta of 1.02. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. During the same period in the prior year, the firm earned ($0.50) EPS. The business's revenue was up 23.9% on a year-over-year basis. Sell-side analysts anticipate that Glaukos Co. will post -1.96 EPS for the current year.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of research analyst reports. Piper Sandler set a $140.00 price target on Glaukos in a report on Thursday, October 17th. Wells Fargo & Company boosted their price target on Glaukos from $135.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Truist Financial increased their price objective on Glaukos from $145.00 to $152.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Needham & Company LLC lifted their target price on shares of Glaukos from $131.00 to $137.00 and gave the company a "buy" rating in a research note on Thursday, August 1st. Finally, JPMorgan Chase & Co. increased their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $134.55.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.